Literature DB >> 22362471

Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma.

Young Eun Chon1, Gi Hong Choi, Myoung Ha Lee, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kyung Sik Kim, Jin Sub Choi, Kwang-Hyub Han, Chae Yoon Chon, Jun Yong Park.   

Abstract

Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) are widely used complementary tumor markers for hepatocellular carcinoma (HCC). In this study, we investigated whether preoperative AFP and DCP levels predict recurrence after curative resection in patients with hepatitis B virus (HBV)-related HCC. Records for 267 patients who were diagnosed with HBV-related HCC and who underwent curative resection for HCC were retrospectively reviewed. Patients were divided into two preoperative groups: pre-op I (AFP ≥ 20 ng/dL and DCP ≥ 40 mAU/mL) and pre-op II (AFP ≥ 20 ng/dL and DCP <40 mAU/mL; AFP <20 ng/dL and DCP ≥ 40 mAU/mL; or AFP <20 ng/dL and DCP <40 mAU/mL). Among 267 patients, 102 (38.2%) patients were classified as pre-op I, whereas the other 165 (61.8%) belonged to pre-op II. During the post-resection follow-up [69.0 (3.0-136.0) months] period, 154 (57.7%) patients developed recurrences [68 (66.7%) patients in pre-op I vs. 86 (52.1%) in pre-op II, p = 0.029]. A multivariate analysis revealed that multiple tumors [hazard ratio (HR), 2.210; 95% confidence interval (CI), 1.185-4.121] and pre-op I (HR: 1.890; 95% CI; 1.080-3.289) were significant predictors for recurrence. Disease-free survival (DFS) was significantly shorter in pre-op I compared to that in pre-op II (20.0 vs. 46.8 months, p = 0.006). Elevated preoperative AFP and DCP levels were associated with a higher recurrence rate and shorter DFS in patients with HBV-related HCC after curative resection. The combined measurement of preoperative AFP and DCP may be a prognostic factor for future recurrence.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22362471     DOI: 10.1002/ijc.27507

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

2.  Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.

Authors:  Makoto Meguro; Toru Mizuguchi; Toshihiko Nishidate; Kenji Okita; Masayuki Ishii; Shigenori Ota; Tomomi Ueki; Emi Akizuki; Koichi Hirata
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

3.  A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese.

Authors:  Fuzhen Qi; Mingde Huang; Yun Pan; Yao Liu; Jibin Liu; Juan Wen; Kaipeng Xie; Hongbing Shen; Hongxia Ma; Yi Miao; Zhibin Hu
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

4.  Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.

Authors:  Hana Park; Jun Yong Park
Journal:  Biomed Res Int       Date:  2013-12-29       Impact factor: 3.411

5.  Alpha-fetoprotein is correlated with intrahepatic recurrence of hepatocellular carcinoma after a hepatectomy.

Authors:  Hyunyou Kim; So Jeong Lee; Myunghee Yoon
Journal:  Ann Surg Treat Res       Date:  2020-03-31       Impact factor: 1.859

6.  Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients.

Authors:  Yang-Xun Pan; Xu-Qi Sun; Zi-Li Hu; Wa Xie; Ke-Xin Nie; Ai-Ping Fang; Ying-Yao Zhang; Yi-Zhen Fu; Jin-Bin Chen; Jun-Cheng Wang; Xin Wang; Yao-Jun Zhang; Dan-Dan Hu; Min-Shan Chen
Journal:  J Hepatocell Carcinoma       Date:  2021-06-25

7.  Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Yong Kang Lee; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang Hun Lee; Do Yun Lee; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  BMC Cancer       Date:  2013-01-03       Impact factor: 4.430

8.  Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Sangheun Lee; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han
Journal:  J Hepatocell Carcinoma       Date:  2015-04-28

9.  The clinical significance of lipopolysaccharide binding protein in hepatocellular carcinoma.

Authors:  Quan-Yu Cai; Jing-Hua Jiang; Ri-Ming Jin; Guang-Zhi Jin; Ning-Yang Jia
Journal:  Oncol Lett       Date:  2019-11-19       Impact factor: 2.967

10.  Effect of delta α-fetoprotein on the detection of liver cancer recurrence.

Authors:  Li-Yue Sun; Yuan He; Qing Liu; Fang Wang
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.